

**PRESS RELEASE**

**12 November 2024 08:00:00 CET**

## **Saniona AB's Nomination Committee for the Annual General Meeting 2025**

**Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announces the composition of the Nomination Committee for the Annual General Meeting 2025**

Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On September 30, 2024, the two largest shareholders, who desired to appoint representatives to the Nomination Committee, were Jørgen Drejer and Joakim Tedroff. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB's Nomination Committee for the Annual General Meeting 2025.

The Nomination Committee's members are:

- Joakim Tedroff, CMO at Irlab Therapeutics AB, appointed by Joakim Tedroff
- Søren Skjærbæk, Partner at Life Science Legal ApS, Vejle, Denmark, appointed by Jørgen Drejer
- Jørgen Drejer, Chairman of Saniona AB's Board

Søren Skjærbæk has been appointed as Chairman of the Nomination Committee.

The Nomination Committee shall prepare and submit proposals to the Annual General Meeting 2025 regarding:

- election of the Chairman at the Annual General Meeting;
- election of the Chairman and other members of the Board;
- remuneration for the Chairman and for each of the other members of the Board and, if applicable, remuneration for committee work;
- election of the auditor and the auditor's remuneration; and
- principles for appointing the Nomination Committee.

The instruction and charter for the Nomination Committee can be found in the Corporate Governance section at the company's website, [www.saniona.com](http://www.saniona.com).

Saniona AB's Annual General Meeting will be held on Wednesday May 28, 2025, in Malmö. The Nomination Committee's proposals will be presented in the notice to the Annual General Meeting and on the company's website.

Shareholders who would like to submit proposals to the Nomination Committee can do so via e-mail to [clo@saniona.com](mailto:clo@saniona.com) marked "Recommendation to the Nomination Committee" or by ordinary mail to the address:

Saniona AB  
Att: Recommendation to the Nomination Committee  
Smedeland 26B  
DK-2600 Glostrup  
Denmark

To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than February 28, 2025.

**For more information, please contact**

Thomas Feldthus, CEO, +45 22109957; [thomas.feldthus@saniona.com](mailto:thomas.feldthus@saniona.com)

**About Saniona**

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona's epilepsy pipeline includes SAN711, a Phase 2-ready candidate for absence seizures; SAN2219, targeting acute repetitive seizures; and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine for obesity is Saniona's most advanced candidate and is out licensed to Medix in Mexico and Argentina. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona partners include Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, visit [www.saniona.com](http://www.saniona.com).

**Attachments**

**[Saniona AB's Nomination Committee for the Annual General Meeting 2025](#)**